Axogen, Inc. (AXGN)
| Market Cap | 697.83M |
| Revenue (ttm) | 107.97M |
| Net Income (ttm) | -24.81M |
| Shares Out | 40.09M |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 27 |
| Last Price | $17.18 |
| Previous Close | $18.35 |
| Change ($) | -1.17 |
| Change (%) | -6.38% |
| Day's Open | 17.92 |
| Day's Range | 17.07 - 18.23 |
| Day's Volume | 363,190 |
| 52-Week Range | 7.35 - 20.09 |
The S&P 500 stocks saw their aggregate trailing 12-month real revenue per share rise at a compound average growth rate (CAGR) of nearly 2% per annum over the past five years. The share price o...
Clinical evidence supporting the company's platform for nerve repair will be featured in several presentations during the scientific sessions Clinical evidence supporting the company's platfor...
ALACHUA, Fla., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...
AxoGen: Operating Efficiencies Come Through The P&L And Cash-flow Statement
ALACHUA, Fla., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2020 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 130.77% and 11.06%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ALACHUA, Fla., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today rep...
ALACHUA, Fla., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral ...
COVID-19 has complicated a sales restructuring effort that was already severely testing the patience of investors, as the company looks to refocus on its core trauma opportunity.
Healthcare veteran brings 30+ years of medtech experience to Axo g en, Inc. Board of Directors
ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...
New data highlights the clinical and economic value of Avance® Nerve Graft compared to nerve autograft New data highlights the clinical and economic value of Avance® Nerve Graft compared to ne...
ALACHUA, Fla., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periphe...
AxoGen's (AXGN) CEO Karen Zaderej on Q2 2020 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 40.00% and 5.31%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., July 29, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periphe...
RECON is a pivotal study supporting the Company’s Biologics License Application (BLA) for Avance® Nerve Graft RECON is a pivotal study supporting the Company’s Biologics License Application (B...
ALACHUA, Fla., July 15, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to periphera...
ALACHUA, Fla., July 01, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Freitag will continue as member of board of directors and serve as special counsel in transitional role through October Freitag will continue as member of board of directors and serve as speci...
ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripher...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q1 2020 Results - Earnings Call Transcript
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., April 23, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today ...
ALACHUA, Fla., March 02, 2020 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q4 2019 Results - Earnings Call Transcript
Largest peripheral nerve repair registry in the world generates clinical evidence of repair, safety, and outcomes data for peripheral nerve injuries Largest peripheral nerve repair registry in...
AxoGen Working Its Way Out Of The Penalty Box, But Execution Is Key
Company will develop an automated bioprocessing system for human tissue scaffolds
Parade float will highlight the life-changing power of tissue and organ donation Parade float will highlight the life-changing power of tissue and organ donation
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q3 2019 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 30.00% and 1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ALACHUA, Fla., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to periph...
Updated outcomes data from the RANGER ® Registry’s MATCH SM cohort will be presented during scientific sessions
Insiders invest in Capri Holdings, General Electric, Sarepta Therapeutics, Ryman Hospitality Properties and Axogen.
CEO of Axogen Inc (30-Year Financial, Insider Trades) Karen L. Zaderej (insider trades) bought 75,000 shares of AXGN on 08/09/2019 at an average price of $13.5 a share.
AxoGen, Inc. (AXGN) CEO Karen Zaderej on Q2 2019 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of 23.08% and -0.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Amidst worries about market size, competition, trial design, and executive turnover, AxoGen has also suffered from a rotation away from growth med-tech that had propelled sector multiples to l...
AxoGen's (AXGN) CEO Karen Zaderej on Q1 2019 Results - Earnings Call Transcript
AxoGen (AXGN) delivered earnings and revenue surprises of -7.14% and 4.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
AxoGen (AXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
About AXGN
AxoGen, together with its subsidiaries, provides surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is u... [Read more...]
| Industry Medical Devices | |
| CEO Karen Zaderej | Employees 371 |
| Stock Exchange NASDAQ | Ticker Symbol AXGN |
Financial Performance
In 2019, Axogen's revenue was $106.71 million, an increase of 27.13% compared to the previous year's $83.94 million. Losses were -$29.14 million, 30.1% more than in 2018.
Analyst Forecasts
According to 7 analysts, the average rating for Axogen stock is "Buy." The 12-month stock price forecast is 21.33, which is an increase of 24.16% from the latest price.